Last reviewed · How we verify
CT-P51
CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
CT-P51 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | CT-P51 |
|---|---|
| Sponsor | Celltrion |
| Drug class | VEGF inhibitor (monoclonal antibody); bevacizumab biosimilar |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CT-P51 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling protein that promotes the formation of new blood vessels. By blocking VEGF, the drug prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a bevacizumab biosimilar developed by Celltrion, it is designed to have comparable efficacy and safety to the reference biologic.
Approved indications
- Metastatic colorectal cancer
- Non-small cell lung cancer
- Metastatic breast cancer
- Renal cell carcinoma
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CT-P51 CI brief — competitive landscape report
- CT-P51 updates RSS · CI watch RSS
- Celltrion portfolio CI